Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
NCT ID: NCT07078994
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
204 participants
INTERVENTIONAL
2025-08-14
2029-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT07080034
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
NCT00102921
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
NCT00306215
Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)
NCT01218360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BCD-261, medium dose induction/ low dose maintenance regimens
Subjects in this arm will receive a medium dose of the BCD-261 during the induction regimen (Weeks 0-12), followed by a transition to a maintenance regimen with a low dose of the BCD-261
anti-TL1A monoclonal antibody, low dose
injection
anti-TL1A monoclonal antibody, medium dose
injection
BCD-261, medium dose induction/ medium dose maintenance regimens
Subjects in this arm will receive a medium dose of the BCD261 during both the induction phase (Weeks 0-12) and the maintenance regimen
anti-TL1A monoclonal antibody, medium dose
injection
BCD-261, high dose induction/ medium dose maintenance regimens
Subjects in this arm will receive a high dose of the BCD-261 during the induction regimen (Weeks 0-12), followed by a transition to a maintenance regimen with a medium dose of the BCD-261
anti-TL1A monoclonal antibody, medium dose
injection
anti-TL1A monoclonal antibody, high dose
injection
BCD-261, high dose induction/ high dose maintenance regimens
Subjects in this arm will receive a high dose of the BCD261 during both the induction phase (Weeks 0-12) and the maintenance regimen
anti-TL1A monoclonal antibody, high dose
injection
Placebo
Subjects in this arm will receive placebo till the assessment of the primary endpoint and then will be switched to BCD-261medium studied dose
Placebo
injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anti-TL1A monoclonal antibody, low dose
injection
anti-TL1A monoclonal antibody, medium dose
injection
anti-TL1A monoclonal antibody, high dose
injection
Placebo
injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Moderate to severe active Crohn's disease, manifested by the following signs:
(1) Crohn's Disease Activity Index (CDAI) ≥220 and ≤450 points.
(2) Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥6 points or ≥4 points for the disease form with isolated involvement of the ileum (according to central independent review).
3\. Inadequate response to therapy according to the investigator's assessment, manifested by at least one of the following signs:
1. Persistent symptoms of disease activity despite treatment with at least one course of glucocorticoids including prednisolone at a dose of ≥40 mg/day or equivalent or budesonide ≥9 mg/day or equivalent for at least 2 weeks with oral administration (at least 1 week with intravenous administration at a dose equivalent to oral prednisolone ≥40 mg/day).
2. Steroid dependence manifested by an increase in disease activity after initial improvement, with a decrease in the dose of glucocorticoids below the dose equivalent to 10 mg of oral prednisolone per day, within 3 months from the beginning of treatment, or a relapse of the disease within 3 months after the end of glucocorticoid use.
3. Persistent symptoms of disease activity despite treatment with at least one course of immunosuppressants (azathioprine at a dose of ≥2.0 mg/kg and/or 6-mercaptopurine at a dose of ≥1.0 mg/kg and/or methotrexate at a dose of ≥15.0 mg/week) for ≥12 weeks, or in response to another treatment regimen with these drugs according to a regional standard of care.
4. Primary lack of response to therapy with TNFa inhibitors and/or anti-integrins, and/or IL-12/23 inhibitors, and/or targeted immunosuppressors (upadacitinib), defined as the persistence of symptoms of disease activity despite at least one course of induction of remission according to a treatment scheme approved by the regional standard.
5. Loss of response to therapy with TNFa inhibitors and/or anti-integrins, and/or IL-12/23 inhibitors, and/or targeted immunosuppressors (upadacitinib), defined as the appearance of symptoms of disease activity after initial improvement as a result of treatment with at least one course of induction of remission and at least one course of maintenance of remission according to a treatment scheme approved by the regional standard.
6. A history of intolerance to glucocorticoid therapy and/or immunosuppressors (azathioprine, 6-mercaptopurine, methotrexate) and/or biologic therapies (TNFα inhibitors, anti-integrins, IL-12/23 inhibitors) and/or targeted immunosuppressors (upadacitinib), as determined by the treating physician.
4\. Maintaining a stable dose of concomitant medications for ≥2 weeks prior to signing the ICF and in the screening period for glucocorticoids and for ≥4 weeks prior to signing the
ICF and in the screening period for immunosuppressants (azathioprine, 6-mercaptopurine, methotrexate).
Exclusion Criteria
2. A history of primary sclerosing cholangitis.
3. Presence of active intra-abdominal or perianal abscess at the time of signing the ICF.
4. Presence of an endoscopically obstructed stricture/stenosis of the intestine at the time of signing the ICF.
5. A history of toxic megacolon, intestinal obstruction, intestinal perforation (except for those caused by injury or appendicitis).
6. A history of dysplasia in any part of the gastrointestinal tract at the time of signing the ICF.
7. Previous resections of the small intestine with a total length of resected segments \>100 cm and/or resection of \>2 segments of the large intestine (ascending colon (including the cecum), transverse colon, descending colon (including the sigmoid colon), rectum)3.
8. Presence of intestinal stoma or artificial rectum or the need for them.
9. Failure of ≥3 classes of biologics/targeted immunosuppressors (according to INN) with different mechanisms of action (TNFa inhibitors, anti-integrins, IL-12/23 inhibitors, upadacitinib) or ≥4 biologics/targeted immunosuppressants (according to INN), regardless of the mechanism of actio
* Use of any of the indicated therapies within the specified time frame or need for therapy with these drugs during the study period:
1. Use of TNFa inhibitors within 8 weeks prior to signing the ICF or during the screening period.
2. Use of anti-integrins or IL-12/23 inhibitors within 12 weeks before signing the ICF or during the screening period.
3. Use of Janus kinase inhibitors (upadacitinib) within 2 weeks prior to signing the ICF or during the screening period.
4. Use of oral glucocorticoids at a dose equivalent to prednisone \>20 mg/day or budesonide \>9 mg/day or rectal administration of glucocorticoids at any dose within 2 weeks prior to signing the ICF or during the screening period or parenteral administration of glucocorticoids at any dose within 4 weeks prior to signing the ICF or during the screening period.
5. Use of immunosuppressants not included in the approved therapy (tacrolimus, cyclosporine, mycophenolate mofetil, rapamycin, leflunomide, penicillamine, etc.) within 4 weeks before signing the ICF or during the screening period.
6. Long-term regular use of non-steroidal anti-inflammatory drugs (≥3 times a week for ≥6 weeks) for 2 weeks prior to signing the ICF.
7. Use of any other investigational drugs in other clinical trials at the time of signing the ICF or less than 8 weeks or 5 half-lives (whichever is longer) before the date of signing the ICF or during screening.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocad
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arina V Zinkina-Orikhan
Role: STUDY_DIRECTOR
Director of Clinical Development Department, BIOCAD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LLC Medical Center "ASTRA"
Barnaul, Altayskiy Kray, Russia
Republican Clinical Hospital named after G.G. Kuvatov
Ufa, Bashkortostan Republic, Russia
State Institution of Healthcare of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
Moscow, Moscow, Russia
Llc "Novosibirsk Gastrocenter"
Novosibirsk, Novosibirsk Oblast, Russia
Federal State Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
Rostov-on-Don, Rostov Oblast, Russia
Federal State Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
Rostov-on-Don, Rostov Oblast, Russia
LLC "Research Center Eco-Safety"
Saint Petersburg, Sankt-Peterburg, Russia
State Autonomous Institution of Healthcare "Republican Clinical Hospital of the Ministry of Healthcare of the Republic of Tatarstan"
Kazan', Tatarstan Republic, Russia
"South Ural State Medical University" of the Ministry of Health of the Russian Federation
Chelyabinsk, , Russia
Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency
Krasnoyarsk, , Russia
Regional State Healthcare Institution "Regional Clinical Hospital
Krasnoyarsk, , Russia
Llc "Olla-Med"
Moscow, , Russia
Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Moscow City Health Department
Moscow, , Russia
State Healthcare Institution of the City of Moscow "V.M. Buyanov City Clinical Hospital of the Moscow City Healthcare Department"
Moscow, , Russia
Branch of the LLC "Hadassah Medical LTD"
Moscow, , Russia
Federal State Educational Institution of Higher Education "North-West State Medical University named after I.I. Mechnikov" of the Ministry of Health of the Russian Federation
Saint Petersburg, , Russia
Saint Petersburg State Healthcare Institution "City Hospital of the Holy Martyr Elizabeth"
Saint Petersburg, , Russia
Federal State Educational Institution of Higher Education "First Saint Petersburg State Medical University named after Academician I.P. Pavlov" of the Ministry of Health of the Russian Federation
Saint Petersburg, , Russia
State Healthcare Institution Ulyanovsk Regional Clinical Hospital
Ulyanovsk, , Russia
State Healthcare Institution "Primorsky Regional Clinical Hospital No. 1"
Vladivostok, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCD-261-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.